| ADR Type | Frequency | Characteristics | Examples |
|---|---|---|---|
| Type A (Augmented) | ~80% | Dose-dependent, predictable, exaggerated pharmacology | Bleeding on warfarin, hypoglycemia on insulin, dry mouth on anticholinergics |
| Type B (Bizarre) | ~15–20% | Dose-independent, unpredictable, immune-mediated | Anaphylaxis, DRESS, SJS/TEN, serum sickness |
| Type C (Chronic) | ~5% | Cumulative dose/duration-dependent | Tetracycline photosensitivity, methotrexate hepatotoxicity |
| Type D (Delayed) | Rare | Teratogenic or carcinogenic | Thalidomide, methotrexate, diethylstilbestrol |
| Type E (End-of-dose) | Uncommon | Withdrawal or rebound phenomena | Rebound hypertension on clonidine withdrawal |
Mnemonic: ADEC — Augmented (most common, 80%), Delayed (rare), End-of-dose (uncommon), Chronic (5%), Bizarre (15–20%, but not in alphabetical order — remember B is second most common).
This is why dose optimization and therapeutic drug monitoring are cornerstone strategies in ADR prevention.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
Daily MCQs, study tips, and topper strategies on Telegram.
Join on Telegram →